Construction method of mouse diabetic nephropathy model for periodic intermittent hypoxia simulation, diabetic nephropathy model and application
The periodic intermittent hypoxia simulation system aggravates the kidney injury in mice, solves the problem of insignificant kidney injury in normal types, and achieves a more accurate simulation of diabetic nephropathy, providing strong support for disease research and treatment strategies.
Patent Information
- Application Number
- CN202411430329.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-14
- Publication Date
- 2024-11-26
AI Technical Summary
In the conventional STZ-induced diabetic nephropathy model of db/db mice, renal injury is not obvious, and it is difficult to effectively simulate the clinical pathological characteristics of diabetic nephropathy.
The periodic intermittent hypoxia simulation system is used to dynamically adjust the oxygen concentration in the chamber, so that mice can live under the cycle of hypoxia and normal oxygen, simulate the hypoxia environment that human diabetic patients may encounter, significantly aggravate the kidney damage in mice. , thereby better simulate the pathological characteristics of diabetic nephropathy.
This method can aggravate kidney damage in mice, simulate the kidney state of diabetic nephropathy patients more accurately, and provide strong experimental support for the research of disease mechanisms and the development of treatment strategies.
Smart Images

Figure CN119014372A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of biomedicine, and more specifically, to a method for constructing a mouse diabetic nephropathy model simulated by periodic intermittent hypoxia, a diabetic nephropathy model and an application thereof. Background Art
[0002] Diabetic nephropathy (DN) is a common and serious chronic complication of diabetes (DM), with an incidence of about 20% to 40%, and is one of the main causes of end-stage renal disease (ESRD). With the increasing number of diabetes patients worldwide, the prevention and treatment of diabetic nephropathy has become an important issue in the medical community.
[0003] The pathogenesis of diabetic nephropathy is complex and involves multiple biological processes. Long-term hyperglycemia is the main cause of diabetic nephropathy. Hyperglycemia leads to renal microvascular lesions, especially damage to the glomeruli and renal tubules, which are mainly manifested as pathological changes such as thickening of the glomerular basement membrane (GBM), proliferation of mesangial matrix, formation of KW nodules, and glomerular sclerosis. These lesions further lead to glomerular filtration dysfunction, causing symptoms such as proteinuria, edema, increased creatinine, oliguria, and may eventually develop into renal failure.
[0004] The kidney injury model is an important tool for studying diabetic nephropathy, among which the STZ-induced db / db mouse model is a commonly used experimental method. However, the effect of this model in simulating kidney injury is usually unsatisfactory, and kidney injury is often not obvious. Therefore, in order to improve the experimental effect of the model and simulate the real kidney injury environment, a model system based on adjustable oxygen concentration is proposed to better simulate the kidney state of patients with diabetic nephropathy, which is of great significance for the study of disease mechanisms and the development of treatment strategies. Summary of the invention
[0005] The purpose of the present invention is to solve the problem that kidney damage is usually not obvious in the conventional STZ-induced db / db mouse diabetic nephropathy model.
[0006] In order to achieve the above-mentioned purpose of the invention, the present application has developed a mouse model system based on periodic intermittent hypoxia (CIH). The system simulates the hypoxic environment that human diabetic patients may encounter by dynamically adjusting the oxygen concentration in the cabin. Through CIH stimulation, the kidney damage of mice can be significantly aggravated, thereby more effectively simulating the clinical pathological characteristics of diabetic nephropathy and providing strong experimental support for the study of disease mechanisms and the development of treatment strategies.
[0007] In a first aspect, the present application provides a method for constructing a mouse diabetic nephropathy model simulated by periodic intermittent hypoxia, comprising: subjecting mice to modeling under cycles of low oxygen concentration and normal oxygen concentration to obtain the mouse diabetic nephropathy model simulated by periodic intermittent hypoxia.
[0008] Furthermore, the low oxygen concentration refers to an oxygen concentration of 6±1%, and the normal oxygen concentration refers to an oxygen concentration of 21±1%.
[0009] Furthermore, the construction method comprises the following steps:
[0010] Step 1: Place mice in a sealed chamber and monitor the oxygen concentration in the environment in real time;
[0011] Step 2, pumping nitrogen to reduce the oxygen concentration in the closed chamber to 6±1% for 60 seconds, then pumping oxygen to restore the oxygen concentration to 21±1% for 60 seconds, which is one cycle;
[0012] Step 3: Repeat the cycle in step 2 for 8 hours a day for 12 weeks.
[0013] Furthermore, during the construction process, the temperature in the cabin was maintained at 21-23°C, and the humidity was maintained at 45-55%. A bright environment was maintained throughout the process to simulate natural light conditions. During the construction process, the mice had free access to food and water to ensure that their basic living needs were met. After the daily modeling was completed, the mice were taken out of the cabin and allowed to recover in a normal environment to reduce the stress and impact of the experiment.
[0014] In a second aspect, the present application provides a mouse diabetic nephropathy model simulated by periodic intermittent hypoxia obtained by the construction method described in the first aspect.
[0015] In a third aspect, the present application provides the use of the mouse diabetic nephropathy model simulated by periodic intermittent hypoxia described in the second aspect in the preparation of diabetic nephropathy detection / diagnosis / prognosis products.
[0016] In a fourth aspect, the present application provides the use of the mouse diabetic nephropathy model simulated by periodic intermittent hypoxia described in the second aspect in the preparation of diabetic nephropathy drugs.
[0017] In summary, this application has the following beneficial effects:
[0018] The construction method of the present application can accurately control the blood oxygen saturation in mice, thereby aggravating kidney damage and better simulating the kidney state of patients with diabetic nephropathy, providing strong experimental support for the study of disease mechanisms and the development of treatment strategies. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 : Evaluation of renal tissue pathological damage in each group of mice in the present application example ( Figure 1 -A represents the HE staining results of kidneys of mice in each group; Figure 1 -B represents the PAS staining results of kidneys of mice in each group; Figure 1 -C represents the glomerular injury score of mice in each group; Figure 1 -D indicates the renal tubular injury score of mice in each group);
[0020] Note: The size of the staining image is ×200, scale bar 50μm; the bar graph results are expressed as mean±SEM, n=6 (rat); *P<0.05vs.WT group; #P<0.05vs.DB group; ΩP<0.05vs.DB+CIH group.
[0021] Figure 2 :CIH promotes renal fibrosis in db / db mice ( Figure 2 -A represents the Masson staining results of kidneys of mice in each group; Figure 2 -B represents the immunohistochemical staining results of Collagen-I in the kidneys of mice in each group; Figure 2 -C indicates the semi-quantitative score of IOD for Collagen-I immunohistochemical staining; Figure 2 -D represents the immunoblotting results of α-SMA and Collagen-I protein expression in the kidneys of mice in each group; Figure 2 -E indicates semi-quantitative analysis of α-SMA and Collagen-I immunoblot band density values);
[0022] Note: The size of the staining image is ×200, and the scale bar is 50 μm. The bar graph results are expressed as mean ± standard error (Mean ± SEM). *P < 0.05 vs. WT group; #P < 0.05 vs. DB group; ΩP < 0.05 vs. DB + CIH group. DETAILED DESCRIPTION
[0023] The technical scheme and effects of the present application are further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the invention, rather than to limit the invention.
[0024] 1. Reagents and sources used in the examples:
[0025]
[0026]
[0027] 2. Experimental instruments and sources used in the examples:
[0028]
[0029]
[0030] Example 1
[0031] (1) Experimental animals
[0032] The db / db mouse is a mouse model with homozygous mutations in the leptin receptor (Lepr) gene, and its main features include polyphagia, early-onset obesity, hyperinsulinemia with insulin resistance, hyperglycemia, and obvious clinical and pathological manifestations of DN. The db / db mouse is a good model for early DN, and its pathological features mainly show glomerular hypertrophy, mesangial matrix expansion and basement membrane thickening, and obvious tubular dilatation, atrophy, shedding and tubulointerstitial fibrosis appear in the late stage of the disease (usually 6 months after the occurrence of DM phenotype). The present embodiment adopts this mouse as a type 2 DN model to carry out this part and subsequent experiments.
[0033] Six-week-old male db / db mice (C57BLKS / J-Leprdb / db) and littermate wild-type controls (C57BLKS / J-LeprWT / WT) were purchased from Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd. The mice were housed in the animal laboratory of Shanghai Sixth People's Hospital (SPF grade). All operations involved in this experiment were approved by the Animal Ethics Committee of Shanghai Sixth People's Hospital.
[0034] (2) Experimental groups
[0035] All mice were adaptively fed to 8 weeks of age, and after blood glucose and body weight were tested and baseline urine was collected, wild-type mice and db / db mice were randomly divided into groups (at least 6 mice were selected in each group), and then modeling and intervention were started. Wild-type mice were divided into 2 groups: normoxic wild-type control group (WT group) and CIH-stimulated wild-type control group (WT+CIH group). db / db mice were divided into 2 groups: normoxic db / db mouse control group (DB group) and CIH-stimulated db / db mouse group (DB+CIH group).
[0036] (3) Establishment of mouse CIH model
[0037] Mice in the normoxic group (WT group and DB group) and mice stimulated by CIH (WT+CIH group, DB+CIH group) were placed in two closed chambers connected to the Biospherix OxyCyler Dynamic O2 Controller. The device can monitor the O2 concentration in the chamber in real time and dynamically change the O2 concentration by injecting oxygen or nitrogen into the chamber according to the settings. The chamber where the normoxic group was located always maintained an O2 concentration of 21±1%, and the chamber where the CIH group was located was set to the following mode: nitrogen was pumped in to reduce the O2 concentration to 6±1% and maintained for a total of 60 seconds, and then oxygen was pumped in to raise the O2 concentration to 21±1% for a total of 60 seconds. Each cycle lasted for 120 seconds, and the cycle process lasted for 8 hours per day (8:00 to 16:00) for a total of 12 weeks. The temperature of the hypoxic chamber was maintained at 21-23°C, the humidity was maintained at 45-55%, and the environment was kept bright throughout the experiment. During the experiment, mice in each group had free access to food and water. After the modeling was completed each day, the mice were taken out and allowed to recover to normal condition.
[0038] (4) Collection of tissue and body fluid specimens
[0039] Before the mice were killed, 24-hour urine was collected from all mice using a mouse-specific metabolic cage and a sterile 15 ml centrifuge tube. The urine was centrifuged at 4°C (3500 rpm, 10 minutes), the supernatant was collected and the urine sediment was discarded, and stored at -80°C for subsequent detection of relevant biochemical indicators.
[0040] After modeling and drug administration for 12 weeks and collecting urine for 24 hours, the mice were anesthetized with 1% sodium pentobarbital, and then the chest and abdominal cavities of the mice were opened, and blood was collected from the abdominal aorta of the mice with a 1ml syringe. The blood samples were left to stand at room temperature for 30 minutes and then centrifuged at 4°C (3500rpm, 15 minutes), and the upper serum was collected and stored at -80°C for subsequent related experimental tests.
[0041] After collecting blood samples from mice, the mice were perfused by heart with 0.9% saline. After observing that the kidneys turned from red to white, the perfused kidneys were removed and the renal capsules were carefully separated, and the weight of the kidneys was measured. The kidneys were then dissected, and two samples were kept for 4% paraformaldehyde fixation and OCT embedding. The remaining samples were separated from the cortex and frozen at -80°C for later use.
[0042] (5) Paraffin-embedded mouse kidney tissue
[0043] ① Fixation: Place the freshly excised mouse kidney into a 4% paraformaldehyde solution 10 times the volume of the kidney and shake it at room temperature for at least 24 hours.
[0044] ② Dehydration, transparency, and wax impregnation: After trimming the kidney tissue section, use a dehydrator to dehydrate the kidney tissue with gradient alcohol, transparentize it with xylene, and wax impregnate it with melted paraffin (65°C). The processing steps are set as follows:
[0045] Reagents Processing time 75% alcohol 4 hours 85% alcohol 2 hours 90% alcohol 2 hours 95% alcohol 1 hour Anhydrous ethanol 1 30 minutes Anhydrous ethanol 2 30 minutes Alcohol benzene 10 minutes Xylene 1 10 minutes Xylene 2 10 minutes Melt paraffin1 1 hour Melted paraffin 2 1 hour Melt paraffin 3 1 hour
[0046] ③Embedding: Embed the wax-impregnated tissue using an embedding machine. Place the fully expanded tissue into an embedding box, cool the solidified wax block in a freezer (-20°C) and trim it.
[0047] ④ Paraffin sectioning: Use a microtome to cut the wax block into 4 μm thin slices along the cross section of the renal tissue. After ironing, quickly place it on a slide treated with anti-shedding and put it in a 37°C oven to dry overnight.
[0048] (6) Kidney hematoxylin-eosin (HE) staining
[0049] ① Baking: Place the paraffin sections of kidney tissue in a 65°C oven and bake for 45 minutes to melt the paraffin on the surface of the tissue.
[0050] ② Dewaxing and hydration: Dewaxing and hydration with gradient alcohol are carried out in a fume hood. The processing steps are as follows:
[0051]
[0052]
[0053] ③Hematoxylin staining: Place the dewaxed and hydrated sections in hematoxylin staining solution for 5 minutes, then wash with distilled water for 1 minute.
[0054] ④ Differentiation: Differentiate the sections with hematoxylin differentiation solution for 2 seconds, and then wash with distilled water for 10 seconds.
[0055] ⑤ Reblueing: Reblue the sections with hematoxylin bluing solution for 2 seconds, then wash with distilled water for 10 seconds.
[0056] ⑥Eosin staining: Dehydrate the blue sections with 95% alcohol for 5 minutes, and then stain them in eosin solution for 5 minutes.
[0057] ⑦ Dehydration and transparency: Dehydration with gradient alcohol and transparency with xylene are carried out in a fume hood. The processing steps are as follows:
[0058] Reagents Processing time 75% alcohol 5 minutes 90% alcohol 5 minutes 95% Alcohol 1 5 minutes 95% Alcohol 2 5 minutes Anhydrous ethanol 1 5 minutes Anhydrous ethanol 2 5 minutes Xylene 1 5 minutes Xylene 2 5 minutes
[0059] ⑧ Sealing: Let the dehydrated transparent slices dry, and seal them with neutral gum, taking care to remove bubbles. Once the slides are completely dry, you can start observing.
[0060] (7) Kidney periodic acid-Schiff (PAS) staining
[0061] ① Baking, dewaxing and hydration: The experimental method is the same as HE staining.
[0062] ②Periodic acid staining: Place the dewaxed and hydrated sections in periodic acid staining solution for 15 minutes, then wash three times with distilled water.
[0063] ③ Schiff staining: Protect from light. Stain the sections in Schiff stain for 30 minutes, then wash with running water for 10 minutes.
[0064] ④ Nuclear staining: Stain the sections with hematoxylin for 5 minutes, then wash and differentiate for 2 seconds, wash again and turn blue for 2 seconds, then rinse with distilled water. The experimental method is the same as HE staining.
[0065] ⑤ Dehydration, transparency and sealing: The experimental method is the same as HE staining.
[0066] (8) Masson staining of kidney
[0067] ① Baking, dewaxing and hydration: The experimental method is the same as HE staining.
[0068] ② Potassium dichromate mordant: Soak the dewaxed and hydrated sections in 2.5% potassium dichromate mordant overnight, then incubate the sections soaked in potassium dichromate in a 65°C oven for 30 minutes, then wash with running water for 30 seconds, and the yellow dye on the tissue surface will fade away.
[0069] ③ Iron hematoxylin nuclear staining: Mix iron hematoxylin A solution and B solution in equal proportions (prepare immediately before use), place the slices into the mixed iron hematoxylin staining solution for 3 minutes, rinse with running water for 10 seconds, and then perform differentiation and blueing (same as HE staining).
[0070] ④ Ponceau staining: Place the sections in Ponceau acid fuchsin solution for staining for 10 minutes. After the tissue turns bright red, wash with running water for 10 minutes.
[0071] ⑤ Phosphomolybdic acid and aniline blue staining: Place the sections in a 1% phosphomolybdic acid aqueous solution for staining for 3 minutes. Drain the sections without washing and directly place them in a 2.5% aniline blue solution for staining for 5 minutes.
[0072] ⑥ Glacial acetic acid differentiation: Place the slices in 1% glacial acetic acid for differentiation for 1 minute.
[0073] ⑦ Dehydration, transparentization and sealing: The experimental method is the same as HE staining.
[0074] (9) Renal pathological injury score
[0075] The HE, PAS and Masson staining of the kidneys of each mouse were observed under an upright fluorescence microscope. The magnification was 400 times, and at least 10 different fields of view were selected for each mouse to take HE and PAS images, and two observers performed quantitative histopathological damage scores to evaluate the histopathological damage of glomeruli and renal tubules.
[0076] ① Glomerular tissue pathological injury score: Glomerular injury is mainly manifested as proliferation and sclerosis of the glomerular mesangial matrix. The specific scores are as follows:
[0077] score describe 0 points Normal glomerular mesangial matrix 1 point Mesangial matrix sclerosis accounts for < 25% of the glomerulus 2 points Sclerosis of the mesangial matrix accounts for 25-50% of the glomerulus 3 points Sclerosis of the mesangial matrix accounts for 50-75% of the glomerulus 4 points Mesangial matrix sclerosis accounts for > 75% of the glomerulus
[0078] ② Tubulointerstitial tissue pathological injury score: Tubulointerstitial injury is mainly manifested as atrophy and dilatation of renal tubules, inflammation and fibrosis in the interstitial area. The specific scores are as follows:
[0079]
[0080]
[0081] (10) Detection of renal protein expression
[0082] ① Extraction of mouse kidney tissue protein:
[0083] Prepare protein lysis working solution by mixing 100× protease inhibitor complex, 100× phosphatase inhibitor complex and RIPA lysis buffer at a ratio of 1:1:98 and pre-cooling on ice. Each sample requires approximately 500 μl.
[0084] Tissue grinding: weigh 10±1 mg of mouse renal cortical tissue, add 500 ul of pre-cooled protein lysis working solution, and then grind the tissue thoroughly using a grinder until the liquid is clear and there are no obvious tissue blocks.
[0085] Lysis: The ground tissue samples were rotated at 4°C for 1 hour to fully lyse.
[0086] Centrifuge and collect samples, centrifuge the lysed tissue at 4°C, 14000 rpm for 20 minutes, and collect the supernatant, which is the obtained protein lysis sample.
[0087] ②BCA method to determine protein concentration:
[0088] Dilute the BCA protein standard by serially diluting the 2000 μg / ml protein standard stock solution with ultrapure water.
[0089] Standard quality control Standard stock solution Ultrapure water Concentration (μg / ml) A 300μl 0μl 2000 B 375μl 125μl 1500 C 325μl 325μl 1000 D 175μl from B 175μl 750 E 325μl from C 325μl 500 F 325μl from E 325μl 250 G 325μl from F 325μl 125 H 100μl from G 400μl 25 I 0μl 400μl 0
[0090] Prepare BCA working solution by mixing Reagent A and Reagent B at a ratio of 50:1 and place on ice for later use.
[0091] Sample addition: Take 5 μl of protein sample and dilute it to 5-fold or 10-fold with RIPA lysis buffer, PBS or ultrapure water at a ratio of 1:4 or 1:9. Add 10 μl of protein standard of each concentration and diluted sample to the 96-well plate. Then add BCA working solution as soon as possible, gently tap the bottom of the well plate to mix evenly, and puncture any remaining bubbles.
[0092] Incubate the mixed well plate at 37°C for 30 minutes.
[0093] Read the absorbance. After the incubation is completed, read the absorbance at 562 nm as soon as possible using an enzyme reader.
[0094] Data processing and balancing, draw a standard linear equation curve based on the absorbance of the test standard and the corresponding concentration, which must satisfy R2>0.99. Calculate the test concentration of each sample according to the curve equation, actual sample concentration = test concentration × dilution factor. Use RIPA lysis buffer, PBS or ultrapure water to prepare all samples to samples with equal protein concentration.
[0095] Denaturation: Mix 5× protein loading buffer and sample in a ratio of 1:4, heat at 95℃ for 10 minutes, and then cool for later use. If long-term storage is required, place at -80℃.
[0096] ③ Detection of protein expression by immunoblotting (Western Blot, WB):
[0097] Prepare electrophoresis gel, and use PAGE gel rapid preparation kit (Yazyme) to prepare separation gel and concentrated gel of different concentrations according to the molecular weight of the target protein to be detected. Wash and assemble the gel preparation plate and glass plate, add the separation gel liquid to the gel preparation plate, seal it with liquid and let it stand at room temperature for 30 minutes to solidify, then prepare the upper concentrated gel and insert the 15-hole comb teeth, let it stand at room temperature for 30 minutes to solidify.
[0098] Protein loading and electrophoresis: Assemble the electrophoresis gel and the vertical electrophoresis tank and electrophoresis gel, and pour in 800ml of electrophoresis buffer. Pull out the comb teeth, wash the wells, add a total of about 30μg of protein sample to each lane, and add 5μl of protein marker at both ends for positioning. Then turn on the electrophoresis instrument, set the voltage to 80V for 40 minutes, and after confirming that all proteins have entered the separation gel, set the voltage to 120V and continue electrophoresis for about 1 hour. Turn off the electrophoresis instrument when the sample containing bromophenol blue is observed to be electrophoresed to the bottom of the instrument.
[0099] Activate the PVDF membrane, cut the PVDF membrane of appropriate size according to the electrophoresis separation gel, and soak the membrane in pre-cooled methanol for 1 minute to fully activate it. Then take out the membrane and place it in the PVDF membrane balancing solution for 1 minute.
[0100] Transfer (semi-dry transfer) using eBlot TML1 fast wet transfer instrument (GenScript L00686C) was used for transfer. Add sufficient 1×PVDF transfer working solution and coolant (ultrapure water) into the instrument. Lay the dry sponge pad, balanced PVDF membrane, and electrophoresis separation gel on the transfer clip in sequence. Use the transfer roller to remove bubbles and lay the second dry sponge pad. Close the transfer clip and insert it into the transfer instrument channel. Select the appropriate transfer time according to the molecular weight of the target protein to be detected and start the transfer (about 10 to 20 minutes).
[0101] Blocking: weigh 2g BSA and dissolve it in 40ml TBST buffer to prepare 5% BSA blocking solution. Separate the transferred PVDF membrane and electrophoresis gel naturally in water, place the membrane in the blocking solution and block it at room temperature for 90 minutes using a gyroscopic oscillator (shaking table).
[0102] Incubate with primary antibody. Dilute the primary antibody in 5% BSA TBST buffer according to the antibody instructions and pre-experiments. Place the blocked PVDF membrane in the primary antibody solution and incubate overnight at 4°C with shaking.
[0103] Wash the membrane and recover the primary antibody solution for reuse. Place the membrane in sufficient TBST buffer and shake at room temperature for 3 times, 5 minutes each time.
[0104] Incubate with secondary antibody, dilute the secondary antibody in TBST buffer at 1:5000. Place the washed PVDF membrane in the secondary antibody solution and incubate at room temperature for 1 hour with shaking. Wash the membrane 3 times after incubation, 5 minutes each time.
[0105] Develop, protect from light. Mix ECL developer A and B in a 1:1 ratio to prepare the developer working solution, and use it within 30 minutes. Place the dried PVDF membrane in the imager and drop the developer working solution on the membrane, incubate for 1 minute. Choose the appropriate exposure time to develop the strips and take pictures.
[0106] Image analysis: The grayscale values of all protein bands obtained were quantitatively analyzed using ImageJ software (National Institutes of Health, Bethesda, MD). The grayscale values of the internal reference protein β-actin or other appropriate proteins of the sample were used for standardization, and the results were expressed as relative band intensity.
[0107] Statistical analysis
[0108] GraphPad Prism 9.0 software (GraphPad Software, San Diego, CA, US) and SPSS22.0 software (IBM, Armonk, NY, US) were used for statistical analysis and drawing. Quantitative data were expressed as mean ± standard error (Mean ± SEM). All data were tested for normality and homogeneity of variance using the Shapiro-Wilk test and Levene test. Two-way ANOVA and Tukey's multiple comparison method and two-sided unpaired t test were used for difference analysis for data with normal distribution and homogeneity of means; Kruskal-Wallis test and Dunn's multiple comparison method and Mann-Whitney U test were used for nonparametric statistics between groups for data that did not meet the normal distribution. P < 0.05 was considered statistically significant.
[0109] Experimental Results
[0110] Depend on Figure 1 It can be seen that in terms of tissue morphology, HE and PAS staining of the kidneys showed that db / db mice had significant renal pathological damage, including swollen glomerular morphology, thickened basement membrane, hyperplasia and sclerosis of the mesangial matrix, dilation of the renal tubular lumen, and disappearance of the brush border structure. We found that there was no significant difference in the glomerular injury score between the DB group and the DB+CIH group, but the renal tubular injury score in the DB+CIH group was significantly higher than that in the DB group. Mice in the DB+CIH group showed more obvious atrophy and shedding of tubular epithelial cells and interstitial inflammatory cell infiltration, indicating that CIH significantly promoted the aggravation of tubulointerstitial damage. In wild-type mice, there was no significant difference in the pathological injury scores between the WT group and the WT+CIH group.
[0111] Depend on Figure 2It can be seen that IFTA is an important pathological feature of DN, and the accumulation of collagen fibers is closely related to the progression of DN and glomerular sclerosis. The results of renal Masson staining showed that CIH caused increased collagen deposition in the kidneys of db / db mice. α-SMA and Collagen-I are important markers of tubulointerstitial fibrosis. α-SMA is an interstitial-specific protein, and its expression is significantly increased when the proximal tubule undergoes EMT to transform into myofibroblast-like cells. Collagen-I, as an important component of renal collagen fibers, is an early marker for assessing the degree of renal fibrosis. Immunohistochemistry results showed that Collagen-I in the kidneys of db / db mice increased significantly under the action of CIH, and was particularly densely expressed in the tubulointerstitial area. Immunoblotting results also showed that the levels of Collagen-I and α-SMA proteins were significantly increased in the kidneys of mice in the DB+CIH group. These results indicate that CIH promotes the degree of renal fibrosis in db / db mice.
[0112] In summary, the construction method of the present application can accurately control the blood oxygen saturation in mice, thereby aggravating kidney damage and better simulating the kidney state of patients with diabetic nephropathy, providing strong experimental support for the study of disease mechanisms and the development of treatment strategies.
[0113] This specific embodiment is merely an explanation of the present application and is not a limitation of the present application. After reading this specification, those skilled in the art may make modifications to the present embodiment without any creative contribution as needed, but such modifications are protected by the patent law as long as they are within the scope of the claims of the present application.
Claims
1. A method for constructing a mouse diabetic nephropathy model simulated by periodic intermittent hypoxia, characterized in that: include: The mice were modeled under the cycle of low oxygen concentration and normal oxygen concentration to obtain the mouse diabetic nephropathy model simulated by periodic intermittent hypoxia.
2. The construction method according to claim 1, characterized in that: The low oxygen concentration refers to an oxygen concentration of 6±1%, and the normal oxygen concentration refers to an oxygen concentration of 21±1%.
3. The construction method according to claim 1, characterized in that: The following steps are involved: Step 1: Place mice in a sealed chamber and monitor the oxygen concentration in the environment in real time; Step 2, pumping nitrogen to reduce the oxygen concentration in the closed chamber to 6±1% for 60 seconds, then pumping oxygen to restore the oxygen concentration to 21±1% for 60 seconds, which is one cycle; Step 3: Repeat the cycle in step 2 for 8 hours a day for 12 weeks.
4. The construction method according to claim 3, characterized in that: During the construction process, the temperature in the cabin was maintained at 21-23°C, and the humidity was maintained at 45-55%. A bright environment was maintained throughout the process to simulate natural light conditions. During the construction process, the mice had free access to food and water to ensure that their basic living needs were met. After the daily modeling was completed, the mice were taken out of the cabin and allowed to recover in a normal environment to reduce the stress and impact of the experiment.
5. A mouse diabetic nephropathy model simulated by periodic intermittent hypoxia obtained by the construction method according to any one of claims 1 to 4.
6. Use of the mouse diabetic nephropathy model simulated by periodic intermittent hypoxia as described in claim 5 in the preparation of diabetic nephropathy detection / diagnosis / prognosis products.
7. Use of the mouse diabetic nephropathy model simulated by periodic intermittent hypoxia according to claim 5 in the preparation of diabetic nephropathy drugs.
